疑似NSTE-ACS患者的早期风险评估:一项回顾性队列研究
该回顾性队列纳入2019年1月1日至2019年7月1日急诊就诊的疑似NSTE-ACS成人患者536例,NSTE-ACS发生134例(25.0%),192例(35.9%)住院。主要终点为急诊就诊期间或住院期间按2020 ESC指南诊断的NSTE-ACS。AUC比较中pre-HEART(0.869;CI 0.835-0.903)、T-MACS(0.862;CI 0.825-0.898)与HEART(0.850;CI 0.815-0.885)表现最佳。98%安全水平下HEART评分表现最好,将28.9%患者判为低危、漏诊0例;pre-HEART将18.3%患者判为低危、漏诊0%。作者认为pre-HEART实用且诊断性能准确,与HEART、T-MACS接近,未来应研究院前评分用于胸痛分诊。
要点
- 536例疑似NSTE-ACS患者中NSTE-ACS 134例(25.0%),192例(35.9%)住院。
- AUC:pre-HEART 0.869(CI 0.835-0.903)、T-MACS 0.862(CI 0.825-0.898)、HEART 0.850(CI 0.815-0.885),三者表现最佳。
- 98%安全水平下HEART评分表现最好,将28.9%患者判为低危、漏诊0例NSTE-ACS。
- 98%安全水平下pre-HEART将18.3%患者判为低危、漏诊0%NSTE-ACS,紧随HEART之后。
- 作者认为pre-HEART实用且诊断性能准确,与HEART、T-MACS接近,未来应研究院前评分用于胸痛分诊以减轻急诊负担。
适用人群与场景
- 2019年1月1日至2019年7月1日急诊就诊、年龄>18岁、疑似NSTE-ACS的患者,共536例。
诊断标准与关键阈值
- 主要终点NSTE-ACS依据2020 ESC指南,定义为急诊就诊期间或住院期间发生的NSTE-ACS。
- 二次分析按95%和98%安全水平判定低危患者数量。
研究设计与关键结果
- 回顾性队列研究,纳入536例疑似NSTE-ACS的急诊成人患者,NSTE-ACS发生134例(25.0%),192例(35.9%)住院。
- AUC比较:pre-HEART 0.869(CI 0.835-0.903)、T-MACS 0.862(CI 0.825-0.898)、HEART 0.850(CI 0.815-0.885)表现最佳。
- 98%安全水平下HEART评分表现最好,将28.9%患者判为低危,漏诊0例NSTE-ACS。
- 98%安全水平下pre-HEART将18.3%患者判为低危,漏诊0%NSTE-ACS。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为pre-HEART评分实用且诊断性能准确,与HEART评分、T-MACS接近。
- 作者认为新的院前风险评分有前景且亟需,未来研究应聚焦院前评分用于胸痛分诊,以减少急诊医疗负担。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Chest pain is among the most common reasons for Emergency Department (ED) presentation, while most patients should be considered low risk for Acute Coronary Syndrome (ACS). Management of these patients places a significant burden on our health care system. Various risk scores have been developed to facilitate the triage of patients with chest pain. However, it remains unclear which score performs best in identifying low risk patients, in various settings. The aim of this study was to determine which risk score performs best in ruling out non-ST elevation ACS (NSTE-ACS).
METHODS: Data was collected from all patients >18 years presenting to the ED between 01 and 01-2019 and 01-07-2019, if they were suspected of NSTE-ACS. Primary endpoint was NSTE-ACS during presentation to the ED or hospitalization, according to the 2020 ESC guidelines. In a secondary analysis we determined the number low-risk patients, at set safety levels of 95% and 98%.
RESULTS: A total of 536 patients were included, 192 (35.9%) were admitted to the hospital and NSTE-ACS occurred in 134 of 536 patients (25.0%). When areas under the curve (AUC) were compared, pre-HEART (0.869; CI 0.835-0.903), T-MACS (0.862; CI 0.825-0.898) and HEART (0.850; CI 0.815-0.885) performed best. At a safety level of 98%, the HEART score was the best performing risk score and identified 28.9% of patients as low risk, and missed 0 cases of NSTE-ACS. Followed by the pre-HEART score, which identified 18.3% of all patients as low risk, and missed 0% of NSTE-ACS.
CONCLUSIONS: The newly developed pre-HEART score is both practical and has accurate diagnostic properties, closely followed by the HEART score, and T-MACS. New pre-hospital risk scores are promising and much needed. Future studies should focus on the usage of pre-hospital scores for triage of patients with chest pain, in order to reduce the burden on emergency health care.
参考来源
- Smulders KRR, Demandt JPA, Vlaar PJ, et al. Early risk assessment in patients with suspected NSTE-ACS; a retrospective cohort study. Am J Emerg Med. 2022. PMID: 35939854. doi:10.1016/j.ajem.2022.07.053
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。